infliximab
…10.Alten R, An Y, Kim DH, Yoon S, Peyrin-Biroulet L. Re-routing infliximab therapy: subcutaneous infliximab opens a path towards greater c…
90articles mentioning drugs
234drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: infliximab ×
infliximab
This drug is selected. Its supporting articles are shown below.
Articles mentioning infliximab
90 articles · page 1 of 8InfliximabCrohn’s ColitisCrohn’s diseasePIBDulcerative colitispaediatric inflammatory bowel disease (PIBD)
…t; 10/23 (43%) patients with available levels were below target.Infliximab is a highly effective therapy in PIBD but adequate induction do…
infliximabmercaptopurineAzathioprineInfliximab-inducedinfliximab-relatedVedolizumabinfliximab-associated
….This case highlights a rare but important dual complication of infliximab therapy in a paediatric patient—pneumonitis and hepatotoxicity—…
InfliximabAdalimumab
…for paediatric UC patients appears to yield similar outcomes to Infliximab. Given these findings, weighing cost-effectiveness and the bene…
infliximabIFXazathioprine
…. 2013;38(4):365–76.Clare DF, Alexander FC, Mike S. Accelerated infliximab infusions are safe and well tolerated in patients with inflamma…
ipilimumabnivolumabinfliximabmycophenolate mofetilinfliximab-associatedirHepatitis
… on Cancer stage IV (8th edition).Results All patients received ipilimumab plus nivolumab. The Eastern Cooperative Oncology Group performa…
infliximabIBD
…D. Patients with the lowest immune infiltration respond best to infliximab, while pan-immune activated patients, driven principally by mon…
infliximabIBD
…ore (FRS) and 13-cell-type Total Immune Burden Score (TIBS) for infliximab response prediction in pre-treatment biopsies (GSE16879; n=61) …
infliximabadalimumabanti-TNFulcerative colitisCrohn’s disease
… anti-TNF (n=37, 26%), p=0.001.In the presence of antibodies to infliximab, 25 (49%) patients immediately changed to an alternative treatm…
infliximabVEOIBD
… (VEOIBD) have been reported to have decreased response rate to infliximab. Younger children have unique drug pharmacokinetics, which risk…
SC-IFXinfliximabRemsimaCrohn’s diseaseNational Institute for Health and Care Excellence
…d 27.5 kgCO2e, expected to be negligible with home-administered SC-IFX.Between February and May 2025, five male adolescents (median ag…
infliximabmethotrexateadalimumabazathioprinehydrocortisoneallopurinolIFXInfliximab-related5-ASA
… M, Green Z, Morris K. OC4 Discontinuation of premedication for infliximab infusions is well-tolerated, without adverse events, and cost-s…